Today's Highlights
Premium
Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab
Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma ( ABUS ) announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combinatio...
P
Prohost Biotech
1 min read
1
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion